Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

NEXT STORY
Trinity Biotech plc to Announce First Quarter Fiscal Year 2018 Financial Results
PREV STORY
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Molecular Templates Presents Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018

ASCO Posters Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas, June 04, 2018 (GLOBE ...

author_avatar
NASDAQ Market News

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

author_avatar
NASDAQ Market News

Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.

author_avatar
NASDAQ Market News